Nurix Therapeutics chief legal officer sells over $149k in shares

Christine Ring, the Chief Legal Officer at Nurix Therapeutics, sold over $149,000 worth of shares in the company on September 2, 2026, through two distinct transactions. The first sale involved 5,387 shares at an average price of $25.6947, while the second saw her sell an additional 400 shares at a weighted average price of $26.6375.

Concurrently, Ring acquired 5,787 shares of Nurix Therapeutics common stock through the exercise of employee stock options, which were granted at a price of $8.72 per share, totaling $50,462. This resulted in her directly owning 9,110 shares of Nurix Therapeutics common stock and holding 117,037 derivative securities in the form of employee stock options.

Analysts have recently adjusted their price targets for Nurix Therapeutics shares following the company's collaboration with Roche, with Mizuho raising its target to $34, Truist Securities to $34, Morgan Stanley to $38, and Baird to $33. The Roche deal is seen as a significant step towards value creation for the company.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.